Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P. DeMatteo,Karla V. Ballman,Cristina R. Antonescu,Robert G. Maki,Peter W.T. Pisters,George D. Demetri,Martin E. Blackstein,Charles D. Blanke,Margaret von Mehren,Murray F. Brennan,Shreyaskumar Patel,Martin D. McCarter,Jonathan Polikoff,Benjamin R. Tan,Kouros Owzar +14 more
Reads0
Chats0
TLDR
Adjuvant imatinib therapy is safe and seems to improve recurrence-free survival compared with placebo after the resection of primary gastrointestinal stromal tumour.About:
This article is published in The Lancet.The article was published on 2009-03-28 and is currently open access. It has received 1217 citations till now. The article focuses on the topics: Imatinib mesylate & Placebo-controlled study.read more
Citations
More filters
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri,Peter Reichardt,Yoon-Koo Kang,Jean-Yves Blay,Piotr Rutkowski,Hans Gelderblom,Peter Hohenberger,Michael F. Leahy,Margaret von Mehren,Heikki Joensuu,Giuseppe Badalamenti,Martin E. Blackstein,Axel Le Cesne,Patrick Schöffski,Robert G. Maki,Sebastian Bauer,Binh Bui Nguyen,Jianming Xu,Toshirou Nishida,John Chung,Christian Kappeler,Iris Kuss,D. Laurent,Paolo G. Casali +23 more
TL;DR: The results of this study show that oral regorafenib can provide a significant improvement in progression-free survival compared with placebo in patients with metastatic GIST after progression on standard treatments.
Journal ArticleDOI
NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
George D. Demetri,Margaret von Mehren,Cristina R. Antonescu,Ronald P. DeMatteo,Kristen N. Ganjoo,Robert G. Maki,Peter W.T. Pisters,Chandrajit P. Raut,Richard F. Riedel,Scott M. Schuetze,Hema Sundar,Jonathan C. Trent,Jeffrey D. Wayne +12 more
TL;DR: The standard of care for managing patients with gastrointestinal stromal tumors (GISTs) rapidly changed after the introduction of effective molecularly targeted therapies involving tyrosine kinase inhibitors (TKIs), such as imatinib mesylate and sunitinib malate.
Journal ArticleDOI
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu,Mikael Eriksson,Kirsten Sundby Hall,Jörg T. Hartmann,Daniel Pink,Jochen Schütte,Giuliano Ramadori,Peter Hohenberger,Justus Duyster,Salah-Eddin Al-Batran,Marcus Schlemmer,Sebastian Bauer,Eva Wardelmann,Maarit Sarlomo-Rikala,Bengt Nilsson,Harri Sihto,Odd R. Monge,Petri Bono,Raija Kallio,Aki Vehtari,M. Leinonen,Thor Alvegård,Peter Reichardt +22 more
TL;DR: Adjuvant imatinib administered for 12 months after surgery has improved recurrence-free survival (RFS) of patients with operable gastrointestinal stromal tumor (GIST) compared with placebo and overall survival of GIST patients with a high risk of Gist recurrence.
Journal ArticleDOI
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts
Heikki Joensuu,Aki Vehtari,Jaakko Riihimäki,Toshirou Nishida,Sonja E. Steigen,Peter Brabec,Lukáš Plank,Bengt Nilsson,Claudia Cirilli,Chiara Braconi,Andrea Bordoni,Magnus K. Magnusson,Zdenek Linke,Jozef Sufliarsky,Massimo Federico,Jon G. Jonasson,Angelo Paolo Dei Tos,Piotr Rutkowski +17 more
TL;DR: Although the modified NIH classification is the best criteria to identify a single high-risk group for consideration of adjuvant therapy, the prognostic contour maps resulting from non-linear modelling are appropriate for estimation of individualised outcomes.
References
More filters
Journal ArticleDOI
Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
Brian J. Druker,Moshe Talpaz,Debra Resta,Bin Peng,Elisabeth Buchdunger,John Ford,Nicholas B. Lydon,Hagop M. Kantarjian,Renaud Capdeville,Sayuri Ohno-Jones,Charles L. Sawyers +10 more
TL;DR: STI571 is well tolerated and has significant antileukemic activity in patients with CML in whom treatment with interferon alfa had failed and demonstrates the potential for the development of anticancer drugs based on the specific molecular abnormality present in a human cancer.
Journal ArticleDOI
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Seiichi Hirota,Koji Isozaki,Yasuhiro Moriyama,Koji Hashimoto,Toshirou Nishida,Shingo Ishiguro,Kiyoshi Kawano,Masato Hanada,Akihiko Kurata,Masashi Takeda,Ghulam Muhammad Tunio,Yuji Matsuzawa,Yuzuru Kanakura,Yasuhisa Shinomura,Yukihiko Kitamura +14 more
TL;DR: Sequencing of c-kit complementary DNA from five GISTs revealed mutations in the region between the transmembrane and tyrosine kinase domains, suggesting that the mutations contribute to tumor development.
Journal ArticleDOI
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more
TL;DR: Imatinib induced a sustained objective response in more than half of patients with an advanced unresectable or metastatic gastrointestinal stromal tumor, indicating that inhibition of the KIT signal-transduction pathway is a promising treatment for advanced gastrointestinalStromal tumors, which resist conventional chemotherapy.
Journal ArticleDOI
Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
Ronald P. DeMatteo,Jonathan J. Lewis,Denis H. Y. Leung,Salvinder S. Mudan,James M. Woodruff,Murray F. Brennan +5 more
TL;DR: Tumor size predicts disease-specific survival in patients with primary disease who undergo complete gross resection and investigational protocols are indicated to reduce the rate of recurrence after resections and to improve the outcome for patients with GIST.
Journal ArticleDOI
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
George D. Demetri,Allan T. van Oosterom,Christopher R. Garrett,Martin E. Blackstein,Manisha H. Shah,Jaap Verweij,Grant A. McArthur,Ian Judson,Michael Heinrich,Jeffrey A. Morgan,Jayesh Desai,Christopher D.M. Fletcher,Suzanne George,Carlo L. Bello,Xin Huang,Charles M. Baum,Paolo G. Casali +16 more
TL;DR: A randomised, double-blind, placebo-controlled, multicentre, international trial to assess tolerability and anticancer efficacy of sunitinib in patients with advanced gastrointestinal stromal tumour, noting significant clinical benefit, including disease control and superior survival.
Related Papers (5)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D. Demetri,Margaret von Mehren,Charles D. Blanke,Annick D. Van den Abbeele,Burton L. Eisenberg,Peter J. Roberts,Michael Heinrich,David A. Tuveson,Samuel Singer,Milos J. Janicek,Jonathan A. Fletcher,Stuart G. Silverman,Sandra Silberman,Renaud Capdeville,Beate Kiese,Bin Peng,Sasa Dimitrijevic,Brian J. Druker,Christopher L. Corless,Christopher D.M. Fletcher,Heikki Joensuu +20 more